Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Author:

Etra Aaron1ORCID,El Jurdi Najla2ORCID,Katsivelos Nikolaos1ORCID,Kwon Deukwoo3,Gergoudis Stephanie1,Morales George1,Spyrou Nikolaos1ORCID,Kowalyk Steven1,Aguayo-Hiraldo Paibel4ORCID,Akahoshi Yu1,Ayuk Francis5,Baez Janna1,Betts Brian C.2,Chanswangphuwana Chantiya6,Chen Yi-Bin7ORCID,Choe Hannah8,DeFilipp Zachariah7ORCID,Gleich Sigrun9,Hexner Elizabeth10ORCID,Hogan William J.11ORCID,Holler Ernst9,Kitko Carrie L.12,Kraus Sabrina13,Al Malki Monzr14ORCID,MacMillan Margaret2,Pawarode Attaphol15,Quagliarella Francesco16ORCID,Qayed Muna17ORCID,Reshef Ran18,Schechter Tal19,Vasova Ingrid20,Weisdorf Daniel2ORCID,Wölfl Matthias21ORCID,Young Rachel1,Nakamura Ryotaro14ORCID,Ferrara James L. M.1,Levine John E.1ORCID,Holtan Shernan2ORCID

Affiliation:

1. 1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

2. 2Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN

3. 3Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

4. 4Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA

5. 5Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

6. 6Blood and Marrow Transplantation Program, Chulalongkorn University, Bangkok, Thailand

7. 7Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA

8. 8Division of Hematology, James Cancer Center, The Ohio State University, Columbus, OH

9. 9Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany

10. 10Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

11. 11Division of Hematology, Mayo Clinic, Rochester, MN

12. 12Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN

13. 13Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

14. 14Hematology/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA

15. 15Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI

16. 16Ospedale Bambino Gesu', Rome, Italy

17. 17Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA

18. 18Blood and Marrow Transplantation Program, Columbia University Medical Center, New York, NY

19. 19Division of Hematology/Oncology/BMT, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

20. 20Med. Klinik III/Poliklinik, Universitatsklinik Erlangen, Erlangen, Germany

21. 21Pediatric Blood and Marrow Transplantation Program, Children’s Hospital, University of Würzburg, Würzburg, Germany

Abstract

Abstract Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of 2 GI GVHD biomarkers (suppressor of tumorigenicity-2 [ST2] + regenerating family member 3 alpha [REG3α]) when measured at GVHD diagnosis are validated predictors of NRM risk but have never been assessed in the same patients using identical statistical methods. We measured the serum concentrations of ST2, REG3α, and AREG by enzyme-linked immunosorbent assay at the time of GVHD diagnosis in 715 patients divided by the date of transplantation into training (2004-2015) and validation (2015-2017) cohorts. The training cohort (n = 341) was used to develop algorithms for predicting the probability of 12-month NRM that contained all possible combinations of 1 to 3 biomarkers and a threshold corresponding to the concordance probability was used to stratify patients for the risk of NRM. Algorithms were compared with each other based on several metrics, including the area under the receiver operating characteristics curve, proportion of patients correctly classified, sensitivity, and specificity using only the validation cohort (n = 374). All algorithms were strong discriminators of 12-month NRM, whether or not patients were systemically treated (n = 321). An algorithm containing only ST2 + REG3α had the highest area under the receiver operating characteristics curve (0.757), correctly classified the most patients (75%), and more accurately risk-stratified those who developed Minnesota standard-risk GVHD and for patients who received posttransplant cyclophosphamide-based prophylaxis. An algorithm containing only AREG more accurately risk-stratified patients with Minnesota high-risk GVHD. Combining ST2, REG3α, and AREG into a single algorithm did not improve performance.

Publisher

American Society of Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3